The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

Canagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose, as well as blood pressure, body weight, and albuminuria in patients with type 2 diabetes mellitus (T2DM). In the CANagliflozin cardioVascular Assessment Study (CANVAS) Program, patients with T2DM and hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Salvatore, Dixon, Dave L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540565/
https://www.ncbi.nlm.nih.gov/pubmed/31138195
http://dx.doi.org/10.1186/s12933-019-0869-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540565/
https://www.ncbi.nlm.nih.gov/pubmed/31138195
http://dx.doi.org/10.1186/s12933-019-0869-2

Ejemplares similares